Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC
Hidenori Toyoda(Ogaki Municipal Hospital), Takashi Matsunaga(Shiga University of Medical Science), Takashi Kumada(Gifu Kyoritsu University), Osamu Yamazaki(Osaka City General Hospital), Tōru Kimura(Josai University), Yuji Kaneoka(Ogaki Municipal Hospital), Fumihiro Urano(Toyohashi Municipal Hospital), Akira Arimoto(Kobe University), Takao Manabe(Osaka City General Hospital), Yukio Osaki(Osaka Red Cross Hospital), Hobyung Chung(Kindai University), Hiroko Oka(Osaka City General Hospital), Masatoshi Kudo(Kindai University)
Cited by 103
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k